Melanoma-related Gene as a Therapeutic Target for Parkinson's Disease
Target Validation, 2014
Objective/Rationale: † † †
Individuals with Parkinsonís disease (PD) are more likely to develop melanoma. Conversely, melanoma patients are at higher risk of developing PD. This bidirectional link suggests a shared genetic basis for these two seemingly distinct conditions.
In collaboration with melanoma researchers, this study seeks to explore a role of a melanoma-related gene in the survival and degeneration of dopamine neurons and the neuroprotective potential of targeting that gene. We will first determine whether toxins cause more damage to pre-clinical models with the inactivated gene. Then we will test whether gene-stimulating drugs protect models against the toxin-induced damage and whether the protective effects disappear with gene inactivation.
Relevance to Diagnosis/Treatment of Parkinsonís Disease: † † † † †
Positive results of the proposed experiments would advance our understanding of the geneís regulation of dopamine-producing neuron survival and death. Evidence that gene-stimulating drugs are protective would foster further investigation and clinical development of existing gene-stimulating drugs or new investment in pursuit of novel treatments for PD.
The insights gained from this project will shed light on a virtually unexplored biological basis of PD and melanoma. They may facilitate further collaborative investigations on a dual role of such gene in cancer and neurodegeneration.
Assistant Professor of Neurology at Massachusetts General Hospital
Location: Boston, Massachusetts, United States
Discover More Grants
Within the Same Program
Within the Same Funding Year